bimatoprost 0.03% ophthalmic solution

DRUG6 trials

Sponsors

Allergan, Tulane University, Assiut University

Conditions

DermatochalasisGeneralized VitiligoGlaucomaOcular Hypertension

Early Phase 1

Topical Bimatoprost for Chemical Blepharoplasty

CompletedNCT02830776

Tulane UniversityDermatochalasis

Start: 2016-11-30End: 2017-06-30Updated: 2021-03-05

Phase 2

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

CompletedNCT00652496

AllerganGlaucoma, Ocular Hypertension

Start: 2005-01-31End: 2005-05-31Updated: 2008-04-03

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT00651859

AllerganGlaucoma, Ocular Hypertension

Start: 2002-11-30End: 2004-01-31Updated: 2008-04-03

Phase 3

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT01099774

AllerganGlaucoma, Ocular Hypertension

Start: 2010-05-01End: 2011-04-29Updated: 2019-04-17

Phase 4

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT01298700

AllerganGlaucoma, Ocular Hypertension

Start: 2011-05-31End: 2016-12-06Updated: 2018-09-17

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

Assiut UniversityGeneralized Vitiligo

Start: 2018-05-31End: 2019-12-31Target: 40Updated: 2018-04-03